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In addition to their cytotoxic activities, natural killer (NK) cells can have immunoregulatory 
functions. We describe a distinct “helper” differentiation pathway of human CD56
 
 
 
CD3
 
 
 
 
NK cells into CD56
 
 
 
/CD83
 
 
 
/CCR7
 
 
 
/CD25
 
 
 
 cells that display high migratory responsiveness 
to lymph node (LN)–associated chemokines, high ability to produce interferon-
 
 
 
 upon 
exposure to dendritic cell (DC)- or T helper (Th) cell–related signals, and pronounced 
abilities to promote interleukin (IL)-12p70 production in DCs and the development of Th1 
responses. This helper pathway of NK cell differentiation, which is not associated with any 
enhancement of cytolytic activity, is induced by IL-18, but not other NK cell–activating 
factors. It is blocked by prostaglandin (PG)E
 
2
 
, a factor that induces a similar CD83
 
 
 
/CCR7
 
 
 
/
CD25
 
 
 
 LN-homing phenotype in maturing DCs. The current data demonstrate independent 
regulation of the “helper” versus “effector” pathways of NK cell differentiation and novel 
mechanisms of immunoregulation by IL-18 and PGE
 
2
 
.
 
Human CD56
 
 
 
/CD3
 
 
 
 NK cells, representing
 
 
 
10% of peripheral blood lymphocytes, were
identified first based on their unique immediate
ability to kill transformed or virally infected cells
(1–3). NK cells are recruited rapidly to the sites
of virus entry, and are critical for controlling
acute viral infections. Individuals who have NK
cell deficits also display recurrent viral infections
(4), which is suggestive of their impaired ability
to develop lasting and effective antigen-specific
recall responses. It was demonstrated that NK
cells play a major immunoregulatory role for
the development of a protective T cell–mediated
immunity against intracellular pathogens and
cancer (5–8). Such “helper” activity of NK cells
is mediated, at least in part, by the functional
modulation of DCs. The phenomenon depends
on the production of IFN-
 
 
 
 and TNF
 
 
 
 by acti-
vated NK cells (9–12), and is associated with the
enhanced induction of Th1 and CTL responses
in human in vitro or mouse in vivo models
(12–14). Despite the identification of these two
distinct functions of NK cells (“helper” versus
“killer”), it remains unclear whether each of
these functions can be induced in the same
subsets of NK cells and at what stages of their
differentiation.
Here we show that in contrast to IL-2—
which selectively promotes the cytotoxic activity
of NK cells—IL-18 does not enhance the cy-
tolytic activity of NK cells, but induces a distinct
“helper” pathway of their differentiation. IL-18,
but not other NK cell–activating cytokines,
promotes the development of CD56
 
 
 
/CD83
 
 
 
/
CCR7
 
 
 
/CD25
 
 
 
 helper NK cells that are
characterized by unique expression of several
mature DC-associated surface markers, high
migratory responsiveness to LN-produced
chemokines, and distinctive abilities to support
IL-12 production in DCs and to promote Th1
responses of CD4
 
 
 
 T cells.
 
RESULTS
IL-2 and IL-18 control different aspects of 
human NK cell activation: LN-homing 
properties of IL-18–primed NK cells
 
The entry of multiple cell types to the T cell
areas of the LNs depends on the LN-produced
CCL19 (MIP-3
 
 
 
/ELC/CK
 
 
 
-11) and CCL21
(6Ckine/SLC/Exodus2/TCA4) ligands for
the chemokine receptor CCR7 (15–17)—and
uniquely in mouse—also CXCR3 (18–20).
Because recent studies demonstrated the presence
of CCR7 expression on a CD56
 
bright
 
/CD16
 
 
 
subpopulation of human blood NK cells and
the presence of NK cells within human LNs
(21–24), we analyzed the activation requirements
that allow freshly isolated resting peripheral
blood NK cells to migrate in response to
lymph node–associated chemokines.
We observed that the addition of LPS (but
not CD40L) to NK cell–macrophage co-cultures
 
CORRESPONDENCE
Pawel Kalinski: 
kalinskip@upmc.edu
 
Abbreviations used: Ag, antigen; 
PG, prostaglandin. 
HELPER PATHWAY OF NK CELL DIFFERENTIATION | Mailliard et al.
 
942
 
induced surface expression of CCR7 on CD56
 
 
 
 NK cells
(Fig. 1 A). This CCR7 expression was no longer restricted
to the CD56
 
bright
 
 subset, which is known to express this
marker constitutively, but appeared with high intensity on
“classic” CD56
 
dim
 
 NK cells (Fig. 1 A). Because such co-
cultures contained low, but distinct, levels of IL-18—the
proinflammatory cytokine that is induced rapidly during
acute infections in tissue-residing DCs and macrophages
(25) and a known NK cell–activating factor during DC–
NK cell interaction (26)—we tested whether recombinant
IL-18 also can induce CCR7. As seen in Fig. 1 B, 100 pg
of IL-18 induced the expression of CCR7 on highly puri-
fied CD56
 
 
 
 (CD3
 
 
 
, CD20
 
 
 
, and MHC II
 
 
 
) NK cells; the
concentrations of 10–1,000 ng/ml were optimally effective
in different donors.
Freshly isolated CD56
 
 
 
 (CD3
 
 
 
, CD20
 
 
 
, and MHC II
 
 
 
)
resting NK cells (Fig. 1 C) showed only marginal migratory
activity in response to CCL21, which was consistent with
the absence of CCR7 expression on the main population of
CD56
 
 
 
(dim)
 
/CD16
 
 
 
 NK cell;, only low levels of CCR7 ex-
pression were observed selectively on the CD56
 
bright
 
/CD16
 
 
 
NK cell subset (Fig. 1, A, C, and D) and only a marginal cy-
totoxic activity was observed against Daudi cells (Fig. 1 F),
which is characteristic of resting NK cells.
Although IL-18 and IL-2 promoted a similar level of
cluster formation in NK cell cultures (Fig. 1 C), each of
Figure 1. Induction of CCR7-responsiveness in NK cells: IL-18 does 
not enhance killer activity of NK cells but induces their migratory 
responsiveness to CCL21. Freshly isolated human NK cells (94% purity, 
with  1% each of CD3 , CD20 , and HLA-DR  cells, see Fig. 2) were 
cultured for 24 or 48 h under serum-free conditions (AIM-V medium) in 
the presence of rhIL-2 or rhIL-18, before their phenotypic and functional 
analyses. (A) NK cells were co-cultured with autologous macrophages in 
the absence or presence of LPS or CD40L for 24 h before harvesting the 
supernatants and the cells. The expression of CCR7 on NK cells is shown 
after gating on CD56 CD3  lymphocytes. n.d., not detected ( 20 pg/ml) 
(B) Freshly-isolated NK cells were cultured for 24 h in the presence of 
increasing concentrations of IL-18 before the analysis of cell surface 
phenotype. Data from one of four experiments with blood of different 
donors that showed the optimum CCR7 induction by 10–1000 ng/ml of 
IL-18. (C–F) Distinct patterns of NK cell activation by IL-2 or IL-18. All data 
were obtained in the same experiment and were reproduced in three addi-
tional donors. (C) IL-2– or IL-18–dependent activation of NK cells results 
in formation of cell clusters in 24-h and 48-h cultures. (D) Surface 
expression of CCR7 induced on NK cells by the exposure to IL-18 (1  g/ml), 
but not IL-2 (250 IU/ml), as determined by flow cytometry. (E) Induction 
of the migratory responsiveness to the LN-associated chemokine CCL21 
(6Ckine; 10 ng/ml) in NK cells treated for 48 h with IL-18, but not IL-2. 
Similar induction of CCL21 responsiveness was observed in 24-h cultures 
of NK cells that were exposed to IL-18 (but not IL-2). Other modes of NK 
activation, such as exposure to IL-1 , IFN- , IL-12, immobilized IgG1, 
and NK cell sensitive targets (K562 and T2 cells), also were tested and 
failed to induce expression of CCR7 unless IL-18 was present (not depicted). 
(F) Cytolytic activity of NK cells against Daudi cells (resistant to killing by 
resting NK cells) is enhanced by the 48-h exposure to IL-2 but not IL-18, 
as demonstrated by 51Cr-release assay. Similar, although less pronounced, 
cytolytic activity against Daudi cells was observed in 24-h IL-2–exposed 
(but not IL-18–exposed) NK cells. As expected, all three populations of 
cultured NK cells expressed strong cytolytic activity against K562 cells 
(not depicted). 
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these factors induced a different pattern of NK cell activa-
tion. Whereas IL-2 selectively enhanced NK cell lytic activ-
ity against Daudi cells (Fig. 1 F), without any impact on the
ability of NK cells to migrate in response to CCL21 (Fig. 1
E), in sharp contrast, IL-18 selectively induced the migratory
responsiveness of NK cells to CCL21, without enhancing
their killer activity. In accordance with the crucial role for
CCR7 in mediating the migratory responses to CCL21 in
the human system (15–17, 19, 20), the above changes were
paralleled by a rapid induction of CCR7 on IL-18–treated
NK cells. This effect was highly selective for IL-18, because
it could not be induced by IL-2 (Fig. 1 D, and Fig. 2), the
factor that is highly effective in priming NK cells for en-
hanced cytotoxic activity (Fig. 1 F), nor by additional NK
cell activators tested: IL-1
 
 
 
, -12, and -15, IFN-
 
 
 
, immobi-
lized IgG, K562, T2, or Daudi targets (not depicted).
These data suggested that IL-18 selectively promotes a
distinct pathway of NK cell activation that is associated with
LN homing, as opposed to the cytotoxic effector pathway of
NK cells differentiation that is induced by IL-2.
High CCR7 expression was induced by IL-18 on the
main population of CD56
 
 
 
 NK cells (CD56
 
dim
 
) that was ex-
posed to IL-18, and was associated with the reduction of their
CD16 expression levels (Fig. 2). In contrast to the optimal in-
duction of cytotoxic activity that required at least 48 h of ex-
posure of NK cells to IL-2, the optimal induction of CCR7
expression was seen after 24 h of exposure to IL-18 (Fig. 2 A).
These IL-18–induced changes occurred in the absence of any
evidence of cell division in CD56
 
dim
 
 or CD56
 
bright
 
 NK cells
(Fig. 2 B), and could be observed in the isolated population of
the flow-sorted CD3
 
 
 
CD56
 
dim
 
 (CD16
 
 
 
) NK cells. This indi-
cated that the IL-18–dependent induction of CCR7
 
 
 
 NK
Figure 2. Rapid induction of CCR7 expression and CCL21 respon-
siveness in IL-18–treated CD56dim NK cells. (A) Phenotypic analysis of 
24-h cultured NK cells demonstrating the increase in CCR7 expression and 
decrease in CD16 expression within the CD56 /CD3  population of NK 
cells upon short-term exposure to rhIL-18, but not IL-2. Dot plots and line 
graphs are shown for visual clarity. Data from one of four experiments that 
yielded similar results. Similar data also were obtained in 48-h cultures. 
Although IL-2 alone was completely ineffective in the induction of CCR7  
expression, it supported the IL-18–induced CCR7 expression. Similar ability 
to support the IL-18–induced CCR7 expression also was observed in the 
case of IL-12 and IFN  (not depicted). (B) Flow-sorted CD56dim NK cells 
develop CCR7  phenotype in 24 h–long IL-18-supplemented cultures. 
Inset: lack of cell division in IL-18–treated cultures of sorted CD56dim (or 
CD56bright) NK cells, as demonstrated by the uniform levels of fluorescence 
of CFSE-labeled NK cells. (C) Flow-sorted CD56dim NK cells develop CCL21 
responsiveness in 24 h–long IL-18–supplemented cultures. 
HELPER PATHWAY OF NK CELL DIFFERENTIATION | Mailliard et al.
 
944
 
cells reflects the differentiation of the cells belonging to the
main population of NK cells, rather than the outgrowth and
differentiation of any cells from the minor population of
CD56
 
bright
 
/CD16
 
 
 
 NK cells or the lineage-negative cells rep-
resenting 2–10% of the negatively isolated NK cells. Our sort-
ing experiments further demonstrated that the CCR7
 
 
 
 NK
cells that were derived from CD56
 
dim
 
 NK cells can develop
into CCL21-responsive cells (Fig. 2 C).
Although IL-2 alone was completely ineffective in in-
ducing CCR7 on resting NK cells, it enhanced the IL-18–
induced CCR7 expression (Fig. 2 A). This suggested that
the acquisition of CCR7
 
 
 
 LN-homing phenotype may be
enhanced during recall phase of immune responses, when
IL-2–producing CD4
 
 
 
 Th cells can interact with DCs in the
peripheral tissues. Similar costimulation of the IL-18–depen-
dent induction of CCR7 on resting NK cells also could be
Figure 3. Unique expression of mature DC–associated surface 
markers and cytokine receptors on IL-18–induced CD83 /CCR7 /
CD25  NK cells. (A) Three-color flow cytometry analysis demonstrates 
coexpression of the mature DC markers CD83, and CD25, on IL-18 induced 
CCR7  population of CD56 /CD16 /CD3 /CD86 /DR  NK cells. Note the 
high expression of receptors for IL-2 (CD25), IL-12, and IFN-  on IL-18–
induced CD56 /CCR7  NK cells. Only low expression of IFN- R  chain, 
and no detectable CD25 and IL-12R 2 were observed on freshly isolated 
resting NK cells (not depicted). Similar data was obtained in two additional 
experiments. Open profiles represent the isotype controls. (B) Prolonged 
culture of IL-18–induced CCR7 /CD83  NK cells in the presence of IL-2 
(added 24 h after IL-18) results in an initial enhancement of CCR7 and 
CD83 expression (up to 40–95% of positive cells in different donors), 
followed by a progressive reduction in their expression, associated with 
increased CD56 and loss of CD16 expression. Note the CD56bright/CD16 /
CCR7dim phenotype of day 6 cultured NK cells (right). The recovery of 
viable NK cells was 70%, 69%, 71%, and 85%, on days 1, 2, 4, and 6, 
respectively, whereas in the absence of IL-2, the cultures showed a rapid 
decline in cell recovery/viability after 48 h of culture (not depicted). Similar 
data were obtained in one additional experiment. (C) Three-color florescent 
microscopy demonstrating the presence of CD3  cells (CD3-positive cells 
are stained blue) coexpressing CD83 (green) and CD56 (red), within the 
T cell areas of LNs (arrows point to yellow cells shown in the enlarged 
photographs). Data from three donors that showed the CD83 expression 
on 8, 16, and 5% of CD3 /CD56  cells in the T cell areas, respectively. 
Coexpression of CD83 and CD56 was verified by confocal microscopic 
analysis (not depicted). Similar cells, although at lower frequency, also 
were observed in the tonsils of two donors (not depicted). 
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observed using other NK cell activating factors, IL-12 or
IFN- , in both cases it was strictly dependent on IL-18 as
the factor permitting the CCR7 induction (not depicted).
IL-18–induced migratory NK cells express CD83: opposing 
roles of prostaglandin E2 in the induction of CD83 /CCR7 /
CD25  DCs and CD83 /CCR7 /CD25  NK cells
The induction of CCR7 on IL-18–treated CD56  NK cells
was accompanied by the induction of CD83, another marker
of mature DCs. Three-color FACS analysis determined that
all of the CCR7  population of IL-18–activated CD56 
NK cells also coexpressed CD83 (Fig. 3 A). Moreover, IL-
18–treated NK cells showed yet another marker of mature
DCs (27), CD25 (  chain of the high-affinity IL-2 receptor),
which suggests that the IL-18–induced CD83 /CCR7 /
CD25  NK cells may home preferentially to the T cell areas
of the LNs and may be primed for a distinct pattern of re-
sponsiveness to such T cell–produced factors as IL-2. Simi-
larly, the enhanced expression of IL-12R 2 and IFN- R 
on CD83 /CCR7 /CD25  NK cells suggested their en-
hanced ability to interact with activated myeloid DCs
(MDCs) and plasmacytoid DCs (PDCs)—which are known
to be sources of IL-12 and IFN- —the factors that are in-
volved in the induction of Th1-type responses.
Although IL-18 by itself did not support the viability of
NK cells (unpublished data), the IL-18–induced CD83 /
CCR7  NK cells could be maintained in IL-2–supple-
mented cultures for at least 6 d. However, although a short-
term exposure to IL-2 resulted in transient enhancement of
CCR7 and CD83 expression, prolonged culture in the pres-
ence of IL-2 (to assure the viability of NK cells) led to the
eventual disappearance of CD83 expression on CCR7  NK
cells, and a strong down-regulation of their CCR7 expres-
sion, in the absence of significant changes in the overall
numbers of cultured NK cells (Fig. 3 B). The reduction of
CD83 and CCR7 expression was accompanied by the loss of
CD16 expression, and the parallel enhancement of the
CD56 levels expressed on NK cell surface (Fig. 3 B).
The expression of CD83 on the IL-18–induced CCR7 
NK cells that were responsive to the LN-associated chemo-
kines raises the question of whether the CD83 molecule can
be used as a reliable selective marker of mature DCs in the
LNs. Triple staining of human LN sections revealed that the
CD83 expression also can be observed on the CD56 /
CD3  cells with NK cell morphology, and frequently juxta-
posed to single-positive CD3  T cells or to single-positive
CD83  cells, in the T cell areas of LNs (Fig. 3 C).
Because the induction of CD83 and CCR7 on maturing
DCs (and the development of their responsiveness to CCR7
ligation) are known to be supported by another inflammatory
mediator prostaglandin (PG)E2 (28, 29), we tested whether
PGE2 also is involved in the regulation of the migratory ca-
Figure 4. Opposing roles of PGE2 in the induction of CD83 /
CCR7 /CD25  DCs versus NK cells. Freshly isolated NK cells or TNF- –
activated monocyte-derived DCs were treated with IL-18, PGE2, or their 
combination. (A) PGE2 supports the induction of the chemokine receptor 
CCR7 on maturing DCs, but prevents the induction of CCR7 expression on 
IL-18–treated NK cells. Although IL-18 does not induce CCR7 expression 
on mature DCs, it does induce the expression of CCR7 and CD83 on NK 
cells. (B) PGE2 prevents the acquisition of the migratory responsiveness to 
CCL21 in IL-18–primed NK cells. Data from one of three experiments that 
produced similar results.HELPER PATHWAY OF NK CELL DIFFERENTIATION | Mailliard et al. 946
pacity of NK cells. In contrast to TNF -activated CD83 
DCs, which responded to PGE2 with the enhanced expression
of CCR7, NK cells did not increase their CCR7 expression
in response to PGE2 alone or in combination with IL-18 (Fig.
4 A). Instead, PGE2 completely blocked the IL-18–dependent
induction of CCR7 and CD83 on NK cells (Fig. 4 A). As ex-
pected, the ability of PGE2 to block CCR7 expression was ac-
companied by its ability to abolish the migratory responsive-
ness of NK cells to CCL21 (Fig. 4 B). Conversely, although
IL-18 primed NK cells for CCR7 expression, it could not re-
place PGE2 in the induction CCR7 expression on TNF -
activated DCs (Fig. 4 A). These data indicate that the CCL21
responsiveness of DCs and NK cells is regulated by different
inflammatory mediators, PGE2 and IL-18, that display oppos-
ing impacts on NK cell activation and acquisition of migratory
responsiveness to LN-associated chemokines.
Migratory CD83 /CCR7 /CD25  NK cells produce IFN-  
upon exposure to Th cell– and DC-related signals: functional 
stability of the “helper” pathway of NK cell differentiation
Induction of LN-homing receptors and CD25 on the IL-18–
treated NK cells prompted us to analyze their responsiveness to
IL-2, a product of activated Th cells, and to other factors that
are likely to be encountered in the T cell areas of the LNs.
IL-18–pretreated NK cells, generated from flow-sorted
CD56dim NK cell population (Fig.  5 A) or from “bulk”
CD56 /CD3  NK cells (Fig. 5, B and C), were washed ex-
tensively to remove IL-18 and were exposed for 24 h to
Figure 5. IL-18–induced LN-homing NK cells produce high levels 
of IFN-  upon subsequent exposure to MDC-, PDC-, or Th cell–related 
signals: functional stability of IL-18–primed NK cells. (A) Flow-sorted 
CD56dim NK cells were treated with IL-18 (1  g/ml) for 24 h before the 
subsequent induction of the IFN-  production with “secondary stimuli.” 
At 24 h, the cells were washed extensively to remove IL-18 and tested 
for their ability to produce IFN-  in response to IL-2, IFN- , or IL-12. 
(B) Freshly isolated “bulk” CD56  NK cells were treated with IL-18 (1  g/ml) 
for 48 h in the absence or presence of PGE2. To analyze the functional 
stability of IL-18–induced NK cells, PGE2 was added at the beginning of 
IL-18-priming cultures, or after 24 h, before the subsequent induction 
of the IFN-  production in IL-18–primed NK cells. At 48 h, the cells were 
washed extensively to remove these factors and tested for their ability to 
produce IFN-  in response to secondary stimuli: IL-2, IFN- , or IL-12. 
Although the addition of PGE2 at the onset of IL-18 priming inhibits NK 
cell responsiveness to the secondary stimuli, delayed addition of PGE2 is 
completely ineffective. Similar data also were obtained when using IL-15 
as a secondary signal (not depicted). (C) IL-18–primed NK cells retain the 
ability to respond to the secondary IFN- –inducing signals, following the 
CCL21-induced migration. (Left panel) NK cells were cultured in the presence 
of IL-18 for 48 h, harvested, and assessed for their migratory responsiveness 
to CCL21 (10 ng/ml) in chemotaxis assay. (Right panel) Following their 
migration, the CCL21-responsive NK cells were tested for their ability to 
produce IFN-  upon the secondary stimulation with IL-2, IFN- , or IL-12. 
  Below the detection limit. Each of the experiments was repeated at 
least two times.JEM VOL. 202, October 3, 2005 947
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IL-2, IFN- , or IL-12, respective products of Th cells, and
PDCs and MDCs. Although the IL-18–pretreated NK cells
did not produce any detectable levels of IFN-  spontane-
ously, their subsequent exposure to IFN- , IL-12, or IL-2
induced high levels of IFN-  production. In accordance
with previous observations that showed the two-signal re-
quirement for efficient IFN-  induction in resting NK cells
(12), control NK cells were not responsive to any of these
individual stimuli (Fig. 5, A–C). In analogy to the CCR7
expression and the responsiveness to LN-associated chemo-
kines, the presence of PGE2 during the IL-18 priming pre-
vented the acquisition of the ability of NK cells to produce
IFN-  in response to subsequent IFN- , IL-12, or IL-2 ex-
posure (Fig. 5 B). PGE2 could prevent the responsiveness of
NK cells to these secondary signals only when it was added
simultaneously with IL-18 (Fig. 5 B) or before this factor
(not depicted). In contrast, the ability of the IL-18–primed
NK cells to produce IFN-  in response to the above LN-
associated stimuli could no longer be suppressed by their sub-
sequent exposure to PGE2; this demonstrated the functional
stability of the IL-18–induced NK cell population (Fig. 5 B).
The functional stability of the IL-18–induced CD83 /
CCR7 /CD25  NK cells was underscored further by their
ability to respond to the IFN- –inducing secondary stimuli
after their CCL21-induced migration and subsequent stimula-
tion of the migrated NK cells (Fig. 5 C). These data also dem-
onstrate formally that the CCR7-mediated migratory func-
tion and the ability to produce IFN-  in response to Th cell
and PDC- and MDC-associated stimuli are expressed by the
same individual IL-18–induced NK cells that codisplay the se-
lectively enhanced LN-homing and IFN- –producing func-
tions, without any enhancement of their cytotoxic functions.
IL-18–induced NK “helper” cells support IL-12p70 
production and promote DC-mediated induction of Th1 
responses, whereas IL-2–primed “cytotoxic” NK cells kill DCs
Because the IL-18–induced CD83 /CCR7 /CD25  NK
cells acquired the migratory responsiveness to secondary
lymphoid tissue–expressed chemokines and the ability to
produce IFN-  upon secondary stimulation with LN-associ-
ated signals, we tested how such IL-18–primed NK cells
would impact mature DCs—the type of DC that is involved
in naive Th cell priming—and the development of Th1 and
Th2 cells from naive CD4  T cells.
Although DCs are resistant to lysis by recently activated
NK cells (12), prolonged NK cell activation can result in the
acquisition of their DC-killing function (11). In accordance
with this last possibility, IL-2–activated “killer” NK cells ef-
ficiently lysed the LPS-matured DCs (Fig. 6 A). In sharp
contrast, IL-18–dependent NK cell activation was not asso-
ciated with the induction of its DC-killing ability against
mature DCs (Fig. 6 A), day 6 immature DCs (not depicted),
or tumor cell targets (Fig. 1 E).
In contrast with the IL-2–primed NK cells that effec-
tively eliminated the encountered DCs, the interaction of
IL-18–pretreated NK cells with DCs resulted in a low, but
distinct, production of IFN- . As shown in Fig. 6, in the
absence of the Th cell–related signal, CD40L, IL-18–
primed NK cells produced only very low levels of IFN- 
upon their interaction with mature DCs. Conversely, ma-
ture DCs that were stimulated with CD40L alone produced
only low levels of IL-12. In accordance with the require-
ment for CD40L stimulation and IFN-  in the effective IL-
12p70 induction in DCs (30, 31), and in turn, with the abil-
ity of IL-12 to induce IFN-  production in IL-18–primed
NK cells (see Fig. 3 A), the presence of IL-18–induced
helper NK cells during the CD40L-dependent DC stimula-
tion resulted in a 10-fold increase in IL-12p70 production,
and an even more pronounced (50-fold) enhancement of
IFN-  production  (Fig. 6). This ability of IL-18–primed
NK cells to support the IL-12 induction in DCs and the
ability of CD40L-dependent signals to enhance the effi-
ciency of NK–DC interaction with regard to the DC-
dependent induction of IFN-  in NK cells and the induc-
tion of IL-12 production by DCs, indicates the existence of
a double-positive feedback that involves the IL-18–primed
Figure 6. IL-2–primed “effector” NK cells kill DCs, whereas IL-18–
primed NK helper cells enhance the ability of DCs to produce IL-12p70. 
(A) NK cells isolated from peripheral blood were treated with IL-2 or IL-18 
for 48 h and used as effectors to test their ability to kill the CD83  DCs 
matured by LPS in a 4-h 51Cr-release assay. (B) LPS-matured DCs were 
stimulated with CD40L-transfected cell line J558 in the absence or pres-
ence of NK helper (NKh) cells. Supernatants were collected at 24 h and 
tested for the presence of IL-12p70 (left panel) and IFN-  (right panel). 
Data from one representative experiment of three performed. Similar 
results also were obtained using soluble rhCD40L instead of J558-CD40L. 
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NK cells, DCs, and naive Th cells during the induction of
Th1-dominated cell-mediated immunity
In accordance with this possibility, and along with the
essential role of IL-12 in the induction and persistence of
functional Th1 responses (32), the presence of the IL-18–
induced NK “helper” cells during priming of naive CD4 
Th cells promoted their Th1 pathway of differentiation,
manifested by their production of enhanced levels of IFN- 
and decreased IL-5 levels upon restimulation (Fig. 7).
DISCUSSION
Our current data demonstrate that in contrast to IL-2 that
selectively promotes the cytotoxic “effector” functions of
NK cells, but may limit their ability to promote the DC-
mediated induction of Th1 responses, IL-18 induces a distinct
“helper” pathway of NK cell differentiation. IL-18–induced
CD56 /CD83 /CCR7 /CD25  helper NK cells express
several surface markers of mature DCs, show high migratory
responses to LN-associated chemokines, and show pro-
nounced abilities to support the IL-12p70 production of
DCs and the induction of Th1 responses of CD4  Th cells.
In analogy to T and B lymphocytes, as well as DCs,
whose functions are guided by the conditions of their prim-
ing, but which become relatively independent from envi-
ronmental cues during their mature/memory/effector phase
of activity (33), the IL-18–induced “helper” subset of NK
cells also displays a striking functional stability. IL-18–primed
NK cells modify the pattern of their responsiveness to such
cytokines as IL-2, IL-12 and IFN- , that is not affected by
the withdrawal of IL-18, nor by subsequent NK cell migra-
tion in response to CCL21, the chemokine that is essential
for the entry of immune cells to the T cell areas of LNs (15–
17). Moreover, although the ability of NK cells to develop
such “helper” function can be prevented effectively at the
stage of NK cell priming by PGE2, an inflammatory media-
tor with Th2-driving activity that is mediated at the level of
Th cells (34–36) and DCs (37), NK cells that have devel-
oped the CD83 /CCR7 /CD25  helper status become re-
sistant to inhibition (Fig. 3 B).
The current data suggest that the reciprocal impact of IL-
18 and PGE2 on the development of helper NK cells consti-
tutes an additional mechanism of the respective Th1- versus
Th2-promoting activities of these factors. Although IL-18,
identified as an IFN- –inducing factor (38), is known to
support IFN-  production in multiple cell types, including
NK cells (25), the ability of IL-18 to induce the migratory
responsiveness of NK cells to CCL21 and to sensitize NK
cells to Th cell–, MDC-, and PDC-associated activating sig-
nals, may make IL-18 especially powerful in promoting the
DC-mediated development of primary Th1 responses. Simi-
larly, although PGE2 can suppress Th1 responses by directly
inhibiting IFN-  production in Th cells and promoting their
alternative Th2 pathway of differentiation (34–36) and by
suppressing the Th1-driving impact of IL-12p70 at the levels
of IL-12 production (37, 39), by suppressing the responsive-
ness to this factor (40) and by inducing IL-12 antagonistic
p40 homodimer (41), the ability of PGE2 to interfere with
the development of LN-homing helper NK cells is likely to
constitute an additional powerful mechanism of the Th2-
promoting activity of PGE2. Such a mechanism is likely to
be particularly strong in chronic inflammatory states where
continued PGE2 overproduction (42, 43) may prevent the
induction of NK cell helper status, and promote a progres-
sive drift toward Th2 immunity in chronic infections, atopic
allergy, or cancer.
IL-18 induced the CCR7 expression selectively on the
main population of CD56 /CD16 /CCR7  blood NK
cells (Fig. 2), rather than the substantially smaller subset of
circulating CD56bright/CD16  NK cells that express low lev-
els of CCR7 without prior activation (22, 24). This sug-
gested that the NK helper status can be induced in most or
all resting NK cells as an alternative to their IL-2-driven “ef-
fector” pathway of differentiation. The CD56bright/CD25 /
CD16 /dim phenotype, induced particularly effectively in the
additional presence of such T cell–derived factors as IL-2, is
similar to the NK cells that are found within secondary lym-
phoid tissue and peripheral blood (22–24, 44). Because the
expression of CD83 disappeared from NK cell surfaces upon
their prolonged culture, the phenomenon associated with
the strong reduction in CCR7 expression, further enhance-
ment of CD56 expression, and complete loss of CD16 from
NK cell surface, it is conceivable that the IL-18–induced
CD56 /CCR7 /CD83 /CD25 /CD16dim NK cells may
represent precursors of the CD56bright/CD16  NK cells that
are present in the LNs that subsequently emigrate to periph-
eral blood and display the ability to produce IFN-  upon
their interaction with activated DCs (22, 24). The presence
of CD56 on a small subset of CD83  cells (classically consid-
ered as a reliable marker of mature DCs) in the T cell areas
of LNs (Fig. 3 C), and to a lesser extent in the inflamed ton-
sils (data not shown), supports this last possibility, although
low frequency of these cells (5–16% of the CD56  cells) did
Figure 7. NK helper cells promote the DC-induced development of 
Th1 cells. In vitro Th cell priming, staphylococcal enterotoxin B–coated 
LPS-matured DCs were used to stimulate naive CD4  Th cell proliferation 
in the absence or presence of  -irradiated (2,000 rad) IL-18–induced 
NK helper (NKh) cells. At day 10, the resulting Th cell cultures were 
restimulated in neutral conditions with activating anti-CD3 and anti-
CD28 antibodies. 24-h supernatants were tested for the presence of the 
respective Th1- and Th2-type cytokines, IFN-  and IL-5. Similar data were 
obtained in one additional experiment.JEM VOL. 202, October 3, 2005 949
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not permit us to isolate and characterize this population with
regard to their function. Low frequency of such cells (at least
in the absence of acute immune responses that are associated
with high IL-18 production), and the possibility of their se-
lective elimination from the sites of chronic inflammation
(by such factors such as PGE2) are in accord with the report
from Ferlazzo and colleagues (23), who observed a strongly
reduced frequency of NK cells in the chronically inflamed
surgically removed tonsils, compared with LNs.
Although we could not observe the expression of CCR7
on  50% of NK cells that were treated with IL-18 alone in
any of the experiments, the additional simultaneous or fol-
low-up exposure of the IL-18–treated cells to IL-2 (or to IL-
12) induced further elevation of CCR7 expression on all of
the NK cells, and was associated with the complete down-
regulation of CD16 expression (Fig. 2 A; Fig. 3 B; not de-
picted). Although the significance of these last observations is
not completely clear, they may represent the ability of Th
cell– or DC-derived signals to transiently stabilize the IL-18–
induced CCR7 expression, and facilitate the effective contri-
bution of NK cells to the Th1 cell priming. After a short pe-
riod of interaction with DCs and activated T cells, NK cells
may down-regulate CCR7 expression and leave the T cell
areas in analogy to antigen (Ag)-activated B cells, whose
short-term transition from B cell follicles to the T cell areas
(to receive T cell helper signals) and back is associated with a
transient induction of CCR7 expression (45). This possibility
is in accord with our observations that although short-term
IL-2 exposure enhances the CCR7 and CD83 expression on
IL-18–treated NK cells (Fig. 2 A), both of these markers are
down-regulated within the subsequent 72–96 h.
Based on the current data and previous reports from hu-
man and mouse systems (9–14), we foresee the following
possible mechanisms of the IL-18– and NK cell–mediated
support for primary Th1 responses. First, peripheral tissue
interaction of NK cells with DCs, in the presence of proin-
flammatory stimuli (e.g., IL-18 and IFN- ), can result in a
stable IFN- – and TNF -mediated polarization of DCs.
This instructs DCs to produce high levels of IL-12 during
subsequent interaction with LN-based naive Th cells and to
induce type-1 responses (12), without the need for tissue-
activated NK cells to enter LNs. A second possibility,
which is supported by the current data, is that the periph-
eral activation of NK cells by IL-18 that is produced by
pathogen-activated macrophages or immature DCs induces
NK cell responsiveness to CCL21 that is produced by lym-
phatic endothelium. This allows NK cell entry into local
lymphatics and their subsequent direct interaction with the
CCL21-producing (46) interdigitating DCs in the T cell
areas of the draining LNs. In this scenario, NK cell–derived
IFN-  can directly co-stimulate the CD40L-induced IL-12
production in DCs that interact with CD40L-expressing
naive Th cells (30, 31) in the T cell areas of LNs, where
NK cells mostly can be seen as adjacent to DCs (Bajenoff,
M., personal communication).
In addition to the CCR7-dependent immigration of NK
cells from pathogen-invaded peripheral tissues, NK cells also
may be recruited directly from circulation, in a process that is
dependent, at least in the mouse, on CXCR3 (13). It remains
unclear whether the CXCR3-mediated pathway allows NK
cells to enter the T cell areas, or facilitates their interaction
with migrating DCs in the marginal zone. In this last sce-
nario, NK cells could deliver the DC-mediated Th1-induc-
ing signals (13) by way of the stable enhancement of the Th1-
and CTL-promoting functions of migrating DCs (12), or
receive the additional IL-18–dependent signal in the marginal
zone to promote their further CCR7-dependent migration
toward the CCL21-producing DCs in the T cell areas.
In the mouse system, although CXCR3 may route NK
cells directly to CCL21-producing DCs in the T cell areas of
the LNs as a result of the ability of mouse CCL21 to interact
with CCR7 and CXCR3 (18), the CCL21–CXCR3 inter-
action may not be applicable to the human system (19, 20).
Therefore, the initial recruitment of human NK cells to the
T cell areas and the resulting first wave of NK cell–depen-
dent IFN-  production are more likely to depend on
CCR7, whereas the IFN- –inducible chemokines, CXCL-9
(MIG), CXCL-10 (IP-10), and CXCL-11 (I-TAC), are
more likely to facilitate later-stage CXCR3-dependent NK
cell recruitment and contribute to the stabilization of a Th1-
type response pattern. In accordance with this last possibility,
although we could not detect the induction of CXCR3 on
IL-18–primed NK cells (not depicted), CXCR3 expression
can be induced upon prolonged IL-2 exposure of human
NK cells (48; not depicted).
In addition to the aforementioned possibilities of the re-
cruitment of NK cells to the LNs under inflammatory con-
ditions, CD56bright NK cells may arise from CD34  precur-
sors directly in the LNs, as indicated by the ability of CD34 
LN precursors to form CD56bright NK cells in cultures that
were supplemented with IL-2 or IL-15 (47).
An intriguing aspect of the current study is the ability of
the IL-2–primed NK cells to kill mature DCs (Fig. 6 A).
During primary responses, the exposure of NK cells to IL-2
represents a verification of the successful induction of CD4 
T cell responses by Ag-carrying DCs, in which case the NK
cell–mediated DC killing may serve a positive role by elimi-
nating the already unnecessary DCs from the LNs. However,
at a later stage of immune responses, NK cells that are pre-
exposed to memory Th cell–produced IL-2 may facilitate the
termination of active immunity by eliminating the subse-
quently encountered Ag-carrying DCs and preventing the
activation of additional T cells. Although the available in vivo
reports uniformly demonstrate a proimmunogenic Th1-driv-
ing role of NK cells (13, 14), the possible autoregulatory role
of IL-2–exposed NK cells in self-limitation of immune re-
sponses (analogous to the IL-2–dependent regulatory T cells
(49, 50), in chronic inflammatory states, autoimmune dis-
eases, or as a limiting factor during the systemic IL-2 treat-
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The current data, which show the ability of NK cells to
acquire CD83 expression, suggest that this last molecule
(CD83) cannot be considered as a selective marker of mature
LN-associated DCs and the circulating mature DC in pe-
ripheral blood (51–53). They highlight a striking similarity
between DCs and NK cells, and between the processes of
DC maturation and the development of the helper status in
NK cells; in both cases, these lead to the acquisition of a dis-
tinct CCR7 /CD83 /CD25  surface phenotype, LN mi-
gratory function, and the ability to interact effectively with
Th cells and with each other. Both of these processes also are
associated with the down-regulation of surface Fc  recep-
tors: CD16 on IL-18–primed NK cells (current data) and
CD32 on maturing DCs (54, 55). At an additional level of
similarity, the inhibitory impact of PGE2 on the priming of
NK cells for subsequent production of IFN-  in response to
Th cell–associated IL-2 closely parallels the ability of PGE2
to suppress the ability of DCs to produce IL-12p70 during
the interaction with CD40L-expressing Th cells (55). The
responsiveness of both of these cell types to PGE2 is termi-
nated at their respective “mature” (55) and “helper” (Fig. 5
A) stages of differentiation.
The current data demonstrate that, depending on the
conditions of their activation, resting NK cells are able to
follow a distinct helper pathway of differentiation, as op-
posed to the “killer” pathway of differentiation. They also
highlight the existence of an additional level of the antago-
nistic activity of IL-18 versus PGE2 in the regulation of the
Th1/Th2 patterns of immune responses that is mediated by
the reciprocal impact of these cytokines on NK cell differen-
tiation. During acute infections—typically associated with
the induction of inflammatory-type immunity—production
of factors (e.g., IL-18, IFN- , TNF ) is likely to promote
the simultaneous accumulation of NK cells and DCs in the
LNs and their interaction, which supports the development
of type-1 responses. Such interaction is likely to be sup-
pressed during chronic phase of immunity, when PGE2 that
is overexpressed at the sites of chronic inflammation (42, 43)
selectively promotes the LN migratory activity of DCs (28,
29), and prevents NK cells from developing their LN-hom-
ing ability and helper activity. These contribute to the pro-
gressive Th1 to Th2 shift that is associated with chronic in-
fections and cancer (56–59).
MATERIALS AND METHODS
Culture media, reagents, and cell lines. Serum-free AIM-V medium
(GIBCO BRL and Invitrogen) was used for short-term culturing of isolated
human NK cells. Cell lines and human DCs were cultured in IMDM con-
taining  L-glutamine supplemented with 1% penicillin/streptomycin and
10% FBS, all of which were purchased from GIBCO BRL. The following
cytokines and reagents were used to culture and activate isolated NK cells,
to obtain immature DCs, to activate and induce maturation of DCs, or to
culture and activate CD4  Th cells: IL-18 (Glaxco-SmithKline); IL-2 (Chi-
ron Corp); IFN-  (Intron A- IFN- -2b; Schering-Plough); rhuIL-12 (Ge-
netics Institute) and soluble trimeric rhCD40L (sCD40LT) (gifts from Im-
munex, Seattle, WA), and purchased from Alexis; rhu GM-CSF and IL-4
(Schering-Plough); rhuTNF-  and rhuIL-1  (both from Strathmann Bio-
tech Gmbh); and PGE2 (Sigma-Aldrich). Anti–human CD3 and CD28
stimulating mAb’s were purchased from CLB. The CD40L-transfected J558
plasmacytoma cell line was a gift from P. Lane (University of Birmingham,
Birmingham, England,UK). The Daudi cell line (susceptible to activated
NK cells, but not resting NK cells) and K562 cells (susceptible to freshly
isolated NK cells) were gifts from T. Whiteside (University of Pittsburgh,
Pittsburgh, PA).
Cell isolation. Mononuclear cells from peripheral blood of healthy donors
were isolated by density gradient separation using Lymphocyte Separation
Medium (Cellgro Mediatech). Resting NK cells (CD56 , CD3 , CD20 ,
HLA-DR ) and naive (CD45RA /RO ) CD4  T cells were isolated by
negative magnetic selection using the StemSep system (StemCell Technolo-
gies Inc.). Isolated populations had  94% purity as determined by flow cy-
tometry; most of the contaminating cells were negative for common lineage
markers. Contamination with CD3 , CD20 , and HLA-DR  cells was each
 1%. When indicated, CD3 CD56dim/CD16  and CD3 /CD56bright/
CD16  NK cell subsets were flow-sorted using MoFlo high-speed cell sorter
(DakoCytomation), after labeling with the appropriate antibodies.
Flow cytometry. Two- and three-color cell surface immunostaining
analysis was performed using a Beckman Coulter Epics XL Flow Cytome-
ter. FITC- and PE-labeled anti–human CD3, CD45RO, CD45RA, CD16,
CD25, and the corresponding isotype (mouse–IgG1) control mAb’s were
purchased from BD Biosciences. FITC- and PE-labeled anti–human CD83
(IgG2b- clone HB15a), CD86 (IgG2b), PC5-labeled anti–human CD56
(IgG1), and the corresponding isotype (FITC- and PE-mouse IgG2b and
PC5-mouse IgG1) control mAb’s were purchased from Coulter Immuno-
tech. The FITC-labeled anti–human CCR7 (IgG2a- clone #150503) mAb
was purchased from R&D Systems; the corresponding control isotype
(mouse IgG2a) was purchased from Coulter Immunotech. Rabbit poly-
clonal antibody against human IFN- R chain 2 ( -chain) was obtained
from Research Diagnostics, Inc. Th antibody against human IL-12R 2
chain was a gift from S.F. Wolf (Genetics Institute, Andover, MA). Before
all stainings, the cells were treated for 15 min in PBS (GIBCO BRL) con-
taining 10% human serum (Atlanta Biologicals) to block nonspecific Fc
binding sites. Immunostaining of cells was performed in PBS buffer, con-
taining 2% human serum, and 0.1% NaN3. Samples were fixed and stored in
a 1% paraformaldehyde solution until cell analysis. For the analysis of NK
cell division, the cells were stained with 5  M CFSE (Invitrogen) for 10
min, before being washed three times and cultured.
NK cell culture. Isolated NK cells were cultured in serum free AIM-V
medium (addition of serum resulted in the inhibition of the IL-18–depen-
dent development of CD83 /CCR7  NK cells) in 48-well plates (Falcon,
Becton Dickinson) at a concentration of 106 cells/m in the absence or pres-
ence of IL-18 (100 pg/ml–1  g/ml). The duration of the short-term cul-
tures of differentially activated NK cells ranged between 24 h and 48 h.
When indicated, NK cells also were exposed to IL-2 (250 IU/ml), IFN- 
(1,000 IU/ml), IL-12 (1 ng/ml), and PGE2 (10 6 M), either alone, in com-
bination with IL-18 (1  g/ml), or after IL-18 pretreatment. Alternatively,
NK cells were co-cultured for 24 h with 6-d GM-CSF–generated (plastic
adherent) macrophages (2  105 cells/ml) in the presence of LPS (250 ng/
ml) or CD40L (1  g/ml).
Cytokine production by NK cells. Cultured NK cells were washed ex-
tensively to remove excess cytokines, placed in fresh AIM-V medium, and
plated in 96-well round bottom plates at 105 cells/200  l/well. The un-
treated control and IL-18–treated NK cells were tested for their ability to
produce IFN-  spontaneously or in response to subsequent exposure to
IL-2 (250 IU/ml), IFN-  (1,000 IU/ml), or IL-12 (1 ng/ml). IFN-  levels
in 24-h supernatant were measured by ELISA.
Cytolytic activity of NK cells. Cytolytic activity was determined by
performing standard 4-h 51Cr-release assays. The results were calculated and
recorded as lytic units or percent target killing as described (12).JEM VOL. 202, October 3, 2005 951
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Three-color in situ analysis of human LN material. All human ma-
terial was obtained under protocols approved by our Institutional Review
Board. Sections (7- m) of noninvolved LNs from patients who underwent
tumor resection were washed in PBS with 4% BSA and labeled with mouse
anti–human CD56-PC5 (Immunotech), followed by Cy3-conjugated Fab
goat anti–mouse mAb (Jackson ImmunoResearch Laboratories) and over-
night blocking with unconjugated Fab goat anti–mouse mAb (Jackson Im-
munoResearch Laboratories). Tissue was incubated with mouse anti–
human CD83 FITC (Immunotech) and rabbit anti–human CD3 mAb
(DakoCytomation) followed by a secondary Alexa 488–labeled goat anti–
mouse (Invitrogen) and goat anti–rabbit Cy5 (Jackson ImmunoResearch
Laboratories). The sections were analyzed using Olympus BX51 fluorescent
microscope (Olympus America Inc.) and Magnafire software (Optoronix).
Generation of human DCs. Human monocytes were isolated from pe-
ripheral blood of healthy donors using a two-step process. Mononuclear
cells were isolated by density gradient separation using Lymphocyte Separa-
tion Medium (Cellgro Mediatech). Monocytes were isolated from mono-
nuclear cell fraction using a Percoll (Sigma-Aldrich) density separation tech-
nique, followed by plastic adherence, as described (36). To obtain immature
“day 6 DCs” (53), monocytes were cultured for 6 d in 24-well plates (Fal-
con, Becton Dickinson) at 5   105 cells per well in IMDM supplemented
with L-glutamine (1%), penicillin/streptomycin (1%), 10% FBS, rhu GM-
CSF, and IL-4 (both 1,000 IU/ml). The typical cultures yielded 2–3   105
per well of CD14 , CD86 , CD83  “immature DCs.”
DC maturation. The following DC maturation factors were used (as de-
scribed in the individual experiments) and added to day 6 DC cultures at
these concentrations: TNF  (50 ng/ml), IL-1  (25 ng/ml), PGE2 (10 6 M),
and LPS (250 ng/ml), as described (41, 55). In all cases, after 48 h, the
CD83  DCs were harvested and analyzed for their expression of matura-
tion-associated surface markers, co-culture with NK cells, and their ability
to produce IL-12p70 in response to CD40L stimulation.
Determination of the IL-12p70-producing capacity of DCs. To de-
termine the IL-12p70–producing capacity of DCs, the cells were harvested,
washed, and plated in flat bottom 96-well plates at 2   104 cells/well and
stimulated with soluble trimeric CD40L protein (1  g/ml), or with
CD40L-transfected J558 cells (5   104) in the presence or absence of differ-
entially activated NK cells (5   104). Supernatants were collected after 24 h
and tested for the presence of IL-12p70 by ELISA.
Cytokine measurements. Concentrations of IL-12p70, IFN- , and IL-5
were determined by specific ELISAs, performed with matched antibody
pairs, standards, and reagents from Endogen. IL-18 concentrations were
measured by ELISA using matched antibody pairs and standards from Med-
ical and Biological Laboratories Co.
Chemotaxis. Chemokine-induced cell migration was measured using the
96-well 5- m pore ChemoTx disposable chemotaxis system (Neuro
Probe). Various concentrations of CCL21 (6C-kine; Biosource Interna-
tional) in AIM-V medium were added to the appropriate wells and below
the membrane. NK cells (3  104 in 30  l AIM-V medium) were placed on
the membrane surface and incubated for 90 min at 37 C. The cells remain-
ing on the topside of the membrane were removed by gentle washing with
cold PBS and wiping, followed by removal of the membrane. The migrated
cells were viewed at the bottom of the wells after gentle centrifugation (2
min at 100 g) of the assay plates. Using an inverted microscope, cells were
examined at 10 , and cell counts within four nonoverlapping random areas
(1 mm2) were recorded. Results are expressed as the mean sum of the four
areas   SEM for duplicate wells. To determine the IFN- –producing ca-
pacity of the CCL21-responsive migratory NK cells, IL-2 (250 IU/ml), IL-
12 (1 ng/ml), or IFN-  (1,000 IU/ml) was added directly to wells contain-
ing the migrated NK cells; 24-h supernatants were collected and analyzed
by ELISA as described earlier.
Differential priming of Th cells. LPS-matured DCs were harvested
and pulsed with staphylococcal enterotoxin B (1 ng/ml) for 1 h (30, 37).
The SEB-coated DCs were washed and placed into culture (2   104 cells/
well) with naive (CD45RA /RO ) CD4  Th cells (105 cells/well) in the
presence or absence of autologous irradiated (2,000 rad) IL-18–treated NK
cells. On day 4, rhIL-2 (50 IU/ml) was added to the cultures. At day 10, the
expanded CD4  Th cells were washed and counted, plated in 96-well
plates (105 cells/well), and stimulated with CD3 (1  g/ml) and CD28 (2
 g/ml) mAb’s (30, 35, 37). The supernatants from restimulated CD4  Th
cells were collected after 24 h and analyzed by ELISA for the presence of
IL-5 and IFN- .
We would like to thank Drs. J. Ortaldo, T. Reinhart, A. Ray, and M. Bajenoff for 
stimulating discussions, critical comments, and sharing unpublished observations.
This work was supported by the National Institutes of Health grant nos. 
CA082016, CA095128, and EA055944, and by The Pittsburgh Foundation Award (to 
P. Kalinski).
The authors have no conflicting financial interests.
Submitted: 14 January 2005
Accepted: 11 August 2005
REFERENCES
1. Herberman, R.B., J. Djeu, H.D. Kay, J.R. Ortaldo, C. Riccardi, G.D.
Bonnard, H.T. Holden, R. Fagnani, A. Santoni, and P. Puccetti. 1979.
Natural killer cells: characteristics and regulation of activity. Immunol.
Rev. 44:43–70.
2. Kiessling, R., and H. Wigzell. 1979. An analysis of the murine NK cell
as to structure, function and biological relevance. Immunol. Rev. 44:
165–208.
3. Timonen, T., J.R. Ortaldo, and R.B. Herberman. 1981. Characteris-
tics of human large granular lymphocytes and relationship to natural
killer and K cells. J. Exp. Med. 153:569–582.
4. Biron, C.A., K.S. Byron, and J.L. Sullivan. 1989. Severe herpesvirus
infections in an adolescent without natural killer cells. N. Engl. J. Med.
320:1731–1735.
5. Colucci, F., M.A. Caligiuri, and J.P. Di Santo. 2003. What does it take
to make a natural killer? Nat. Rev. Immunol. 3:413–425.
6. Cooper, M.A., T.A. Fehniger, A. Fuchs, M. Colonna, and M.A.
Caligiuri. 2004. NK cell and DC interactions. Trends Immunol. 25:47–52.
7. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in
abused tissues. Nat. Rev. Immunol. 2:957–964.
8. Ferlazzo, G., and C. Munz. 2004. NK cell compartments and their ac-
tivation by dendritic cells. J. Immunol. 172:1333–1339.
9. Ferlazzo, G., M.L. Tsang, L. Moretta, G. Melioli, R.M. Steinman, and
C. Munz. 2002. Human dendritic cells activate resting natural killer
(NK) cells and are recognized via the NKp30 receptor by activated NK
cells. J. Exp. Med. 195:343–351.
10. Gerosa, F., B. Baldani-Guerra, C. Nisii, V. Marchesini, G. Carra, and
G. Trinchieri. 2002. Reciprocal activating interaction between natural
killer cells and dendritic cells. J. Exp. Med. 195:327–333.
11. Piccioli, D., S. Sbrana, E. Melandri, and N.M. Valiante. 2002. Con-
tact-dependent stimulation and inhibition of dendritic cells by natural
killer cells. J. Exp. Med. 195:335–341.
12. Mailliard, R.B., Y.I. Son, R. Redlinger, P.T. Coates, A. Giermasz, P.A.
Morel, W.J. Storkus, and P. Kalinski. 2003. Dendritic cells mediate NK
cell help for Th1 and CTL responses: two-signal requirement for the in-
duction of NK cell helper function. J. Immunol. 171:2366–2373.
13. Martin-Fontecha, A., L.L. Thomsen, S. Brett, C. Gerard, M. Lipp, A.
Lanzavecchia, and F. Sallusto. 2004. Induced recruitment of NK cells
to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immu-
nol. 5:1260–1265.
14. Mocikat, R., H. Braumuller, A. Gumy, O. Egeter, H. Ziegler, U. Reusch,
A. Bubeck, J. Louis, R. Mailhammer, G. Riethmuller, et al. 2003. Natu-
ral killer cells activated by MHC class I(low) targets prime dendritic cells
to induce protective CD8 T cell responses. Immunity. 19:561–569.
15. Sallusto, F., C.R. Mackay, and A. Lanzavecchia. 2000. The role of
chemokine receptors in primary, effector, and memory immune re-HELPER PATHWAY OF NK CELL DIFFERENTIATION | Mailliard et al. 952
sponses. Annu. Rev. Immunol. 18:593–620.
16. Weninger, W., and U.H. von Andrian. 2003. Chemokine regulation of
naive T cell traffic in health and disease. Semin. Immunol. 15:257–270.
17. Moser, B., and P. Loetscher. 2001. Lymphocyte traffic control by che-
mokines. Nat. Immunol. 2:123–128.
18. Jenh, C.H., M.A. Cox, H. Kaminski, M. Zhang, H. Byrnes, J. Fine, D.
Lundell, C.C. Chou, S.K. Narula, and P.J. Zavodny. 1999. Cutting
edge: species specificity of the CC chemokine 6Ckine signaling
through the CXC chemokine receptor CXCR3: human 6Ckine is not
a ligand for the human or mouse CXCR3 receptors. J. Immunol. 162:
3765–3769.
19. Soto, H., W. Wang, R.M. Strieter, N.G. Copeland, D.J. Gilbert, N.A.
Jenkins, J. Hedrick, and A. Zlotnik. 1998. The CC chemokine 6Ckine
binds the CXC chemokine receptor CXCR3. Proc. Natl. Acad. Sci.
USA. 95:8205–8210.
20. Wang, X., X. Li, D.B. Schmidt, J.J. Foley, F.C. Barone, R.S. Ames,
and H.M. Sarau. 2000. Identification and molecular characterization of
rat CXCR3: receptor expression and interferon-inducible protein-10
binding are increased in focal stroke. Mol. Pharmacol. 57:1190–1198.
21. Cooper, M.A., T.A. Fehniger, S.C. Turner, K.S. Chen, B.A. Ghaheri,
T. Ghayur, W.E. Carson, and M.A. Caligiuri. 2001. Human natural
killer cells: a unique innate immunoregulatory role for the CD56
(bright) subset. Blood. 97:3146–3151.
22. Fehniger, T.A., M.A. Cooper, G.J. Nuovo, M. Cella, F. Facchetti, M.
Colonna, and M.A. Caligiuri. 2003. CD56bright natural killer cells are
present in human lymph nodes and are activated by T cell-derived
IL-2: a potential new link between adaptive and innate immunity.
Blood. 101:3052–3057.
23. Ferlazzo, G., D. Thomas, S.L. Lin, K. Goodman, B. Morandi, W.A.
Muller, A. Moretta, and C. Munz. 2004. The abundant NK cells in hu-
man secondary lymphoid tissues require activation to express killer cell
Ig-like receptors and become cytolytic. J. Immunol. 172:1455–1462.
24. Vitale, M., M. Della Chiesa, S. Carlomagno, C. Romagnani, A. Thiel,
L. Moretta, and A. Moretta. 2004. The small subset of CD56
brightCD16- natural killer cells is selectively responsible for both cell
proliferation and interferon-gamma production upon interaction with
dendritic cells. Eur. J. Immunol. 34:1715–1722.
25. Akira, S. 2000. The role of IL-18 in innate immunity. Curr. Opin. Im-
munol. 12:59–63.
26. Semino, C., G. Angelini, A. Poggi, and A. Rubartelli. 2005. NK/iDC
interaction results in IL-18 secretion by DCs at the synaptic cleft fol-
lowed by NK cell activation and release of the DC maturation factor
HMGB1. Blood. 106:609–616.
27. Zhou, L.J., and T.F. Tedder. 1995. A distinct pattern of cytokine gene ex-
pression by human CD83  blood dendritic cells. Blood. 86:3295–3301.
28. Scandella, E., Y. Men, S. Gillessen, R. Forster, and M. Groettrup.
2002. Prostaglandin E2 is a key factor for CCR7 surface expression and
migration of monocyte-derived dendritic cells. Blood. 100:1354–1361.
29. Luft, T., M. Jefford, P. Luetjens, T. Toy, H. Hochrein, K.A. Master-
man, C. Maliszewski, K. Shortman, J. Cebon, and E. Maraskovsky.
2002. Functionally distinct dendritic cell (DC) populations induced by
physiologic stimuli: prostaglandin E(2) regulates the migratory capacity
of specific DC subsets. Blood. 100:1362–1372.
30. Hilkens, C.M., P. Kalinski, M. de Boer, and M.L. Kapsenberg. 1997.
Human dendritic cells require exogenous interleukin-12-inducing fac-
tors to direct the development of naive T-helper cells toward the Th1
phenotype. Blood. 90:1920–1926.
31. Snijders, A., P. Kalinski, C.M. Hilkens, and M.L. Kapsenberg. 1998.
High-level IL-12 production by human dendritic cells requires two
signals. Int. Immunol. 10:1593–1598.
32. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resis-
tance and adaptive immunity. Nat. Rev. Immunol. 3:133–146.
33. Kalinski, P., C.M. Hilkens, E.A. Wierenga, and M.L. Kapsenberg.
1999. T-cell priming by type-1 and type-2 polarized dendritic cells:
the concept of a third signal. Immunol. Today. 20:561–567.
34. Hilkens, C.M., H. Vermeulen, R.J. van Neerven, F.G. Snijdewint,
E.A. Wierenga, and M.L. Kapsenberg. 1995. Differential modulation
of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion
by prostaglandin E2 critically depends on interleukin-2. Eur. J. Immu-
nol. 25:59–63.
35. Snijdewint, F.G., P. Kalinski, E.A. Wierenga, J.D. Bos, and M.L.
Kapsenberg. 1993. Prostaglandin E2 differentially modulates cytokine
secretion profiles of human T helper lymphocytes. J. Immunol. 150:
5321–5329.
36. Betz, M., and B.S. Fox. 1991. Prostaglandin E2 inhibits production of Th1
lymphokines but not of Th2 lymphokines. J. Immunol. 146:108–113.
37. Kalinski, P., C.M. Hilkens, A. Snijders, F.G. Snijdewint, and M.L.
Kapsenberg. 1997. IL-12-deficient dendritic cells, generated in the
presence of prostaglandin E2, promote type 2 cytokine production in
maturing human naive T helper cells. J. Immunol. 159:28–35.
38. Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T.
Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995.
Cloning of a new cytokine that induces IFN-gamma production by T
cells. Nature. 378:88–91.
39. van der Pouw Kraan, T.C., L.C. Boeije, R.J. Smeenk, J. Wijdenes,
and L.A. Aarden. 1995. Prostaglandin-E2 is a potent inhibitor of hu-
man interleukin 12 production. J. Exp. Med. 181:775–779.
40. Wu, C.Y., K. Wang, J.F. McDyer, and R.A. Seder. 1998. Prostaglan-
din E2 and dexamethasone inhibit IL-12 receptor expression and IL-12
responsiveness. J. Immunol. 161:2723–2730.
41. Kalinski, P., P.L. Vieira, J.H. Schuitemaker, E.C. de Jong, and M.L.
Kapsenberg. 2001. Prostaglandin E(2) is a selective inducer of interleu-
kin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-
12p70 heterodimer. Blood. 97:3466–3469.
42. Kuehl, F.A., Jr., and R.W. Egan. 1980. Prostaglandins, arachidonic
acid, and inflammation. Science. 210:978–984.
43. Phipps, R.P., S.H. Stein, and R.L. Roper. 1991. A new view of pros-
taglandin E regulation of the immune response. Immunol. Today. 12:
349–352.
44. Carson, W.E., T.A. Fehniger, and M.A. Caligiuri. 1997. CD56bright
natural killer cell subsets: characterization of distinct functional responses
to interleukin-2 and the c-kit ligand. Eur. J. Immunol. 27:354–360.
45. Reif, K., E.H. Ekland, L. Ohl, H. Nakano, M. Lipp, R. Forster, and
J.G. Cyster. 2002. Balanced responsiveness to chemoattractants from
adjacent zones determines B-cell position. Nature. 416:94–99.
46. Willimann, K., D.F. Legler, M. Loetscher, R.S. Roos, M.B. Delgado,
I. Clark-Lewis, M. Baggiolini, and B. Moser. 1998. The chemokine
SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid
tissues and attracts activated T cells via CCR7. Eur. J. Immunol. 28:
2025–2034.
47. Castriconi, R., C. Cantoni, M. Della Chiesa, M. Vitale, E. Marcenaro,
R. Conte, R. Biassoni, C. Bottino, L. Moretta, and A. Moretta. 2003.
Transforming growth factor beta 1 inhibits expression of NKp30 and
NKG2D receptors: consequences for the NK-mediated killing of den-
dritic cells. Proc. Natl. Acad. Sci. USA. 100:4120–4125.
48. Freud, A.G., B. Becknell, S. Roychowdhury, H.C. Mao, A.K. Ferket-
ich, G.J. Nuovo, T.L. Hughes, T.B. Marburger, J. Sung, R.A. Baiocchi,
et al. 2005. A human CD34( ) subset resides in lymph nodes and differ-
entiates into CD56bright natural killer cells. Immunity. 22:295–304.
49. Hori, S., T. Takahashi, and S. Sakaguchi. 2003. Control of autoimmu-
nity by naturally arising regulatory CD4  T cells. Adv. Immunol. 81:
331–371.
50. Curotto de Lafaille, M.A., and J.J. Lafaille. 2002. CD4( ) regulatory T
cells in autoimmunity and allergy. Curr. Opin. Immunol. 14:771–778.
51. Weissman, D., Y. Li, J. Ananworanich, L.J. Zhou, J. Adelsberger, T.F.
Tedder, M. Baseler, and A.S. Fauci. 1995. Three populations of cells
with dendritic morphology exist in peripheral blood, only one of
which is infectable with human immunodeficiency virus type 1. Proc.
Natl. Acad. Sci. USA. 92:826–830.
52. Zhou, L.J., R. Schwarting, H.M. Smith, and T.F. Tedder. 1992. A
novel cell-surface molecule expressed by human interdigitating reticu-
lum cells, Langerhans cells, and activated lymphocytes is a new mem-
ber of the Ig superfamily. J. Immunol. 149:735–742.
53. Zhou, L.J., and T.F. Tedder. 1995. Human blood dendritic cells selec-
tively express CD83, a member of the immunoglobulin superfamily. J.
Immunol. 154:3821–3835.JEM VOL. 202, October 3, 2005 953
ARTICLE
54. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble
antigen by cultured human dendritic cells is maintained by granulocyte/
macrophage colony-stimulating factor plus interleukin 4 and downregu-
lated by tumor necrosis factor alpha. J. Exp. Med. 179:1109–1118.
55. Kalinski, P., J.H. Schuitemaker, C.M. Hilkens, and M.L. Kapsenberg.
1998. Prostaglandin E2 induces the final maturation of IL-12-deficient
CD1a CD83  dendritic cells: the levels of IL-12 are determined dur-
ing the final dendritic cell maturation and are resistant to further mod-
ulation. J. Immunol. 161:2804–2809.
56. Clerici, M., G.M. Shearer, and E. Clerici. 1998. Cytokine dysregula-
tion in invasive cervical carcinoma and other human neoplasias: time to
consider the TH1/TH2 paradigm. J. Natl. Cancer Inst. 90:261–263.
57. Kapsenberg, M.L., E.A. Wierenga, J.D. Bos, and H.M. Jansen. 1991.
Functional subsets of allergen-reactive human CD4  T cells. Immunol.
Today. 12:392–395.
58. Romagnani, S. 1994. Lymphokine production by human T cells in dis-
ease states. Annu. Rev. Immunol. 12:227–257.
59. Shurin, M.R., L. Lu, P. Kalinski, A.M. Stewart-Akers, and M.T.
Lotze. 1999. Th1/Th2 balance in cancer, transplantation and preg-
nancy. Springer Semin. Immunopathol. 21:339–359.